Insulin therapy with lispro mix 50/50 t.i.d. is a treatment with a single insulin device. The
management is comparatively simple and easy, but the curative effect is promising. It is also
reported that noninferiority has been observed between basal/bolus therapy (BBT) and prandial
premixed therapy (PPT, lispro mix 50/50 t.i.d.).
The purpose of this study is to evaluate whether change of insulin therapy from BBT
(long-acting insulin at bedtime plus mealtime rapid-acting insulin) or analog insulin therapy
t.i.d. (including therapies with aspart mix 70/30 and lispro mix 75/25) to lispro mix 50/50
t.i.d. improves glycemic control of patients with type 2 diabetes mellitus.